New Technology– category –
-
Breakthrough: EU Approves Oral BTK Inhibitor Tolebrutinib as First Disability-Targeting Therapy for Nonrelapsing SPMS
NeurologyLive Europe Overview The European Commission has approved Sanofi's oral, brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib (Cenrifki), for nonrelapsing secondary progressive multiple sclerosis (SPMS). This a... -
AI-Enabled Assay Discovers 31 Anti-Aging Compounds from 2,782 FDA-Approved Drugs, Extending C. elegans Lifespan
bioRxiv International Overview A bioRxiv preprint describes an open-source AI-enabled screening platform using C. elegans to rapidly identify geroprotective drugs. The platform screened 2,782 FDA-approved compounds, identifying 31 agents... -
BMS’s First CELMoD Therapy ZENBEXUS™ Receives Accelerated FDA Approval in Combination with Daratumumab for Multiple Myeloma, Including Early Relapse Patients
Bristol Myers Squibb USA Overview The U.S. FDA granted accelerated approval to Bristol Myers Squibb's first Cereblon E3 ligase modulator (CELMoD) therapy, ZENBEXUS™ (iberdomide), in combination with daratumumab, hyaluronidase-fihj, and d... -
FDA Grants Accelerated Approval to Replimune’s Onco-Viral Therapy Tudriqev in Combination with Nivolumab for Advanced Melanoma, Offering New Treatment Option
U.S. Food and Drug Administration USA Overview The U.S. FDA granted accelerated approval to Replimune, Inc.'s oncolytic viral therapy Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adult patients with advance... -
Ractigen Therapeutics Completes Phase II Enrollment for SOD1-ALS siRNA RAG-17; LiCO Therapy RAG-18 for DMD Receives Rare Pediatric Disease Designation
Facebook China Overview Ractigen Therapeutics announced the completion of patient enrollment and first dosing in its Phase II clinical trial for RAG-17, an investigational siRNA therapy for SOD1-mutated amyotrophic lateral sclerosis (ALS... -
Comprehensive Guide Published: RNA Therapeutics, from ASO to LNP/GalNAc Platforms, Shaping the Future of Precision Medicine
MDPI International Overview A comprehensive guide published by MDPI overviews the engineering history of RNA therapeutics, spanning from ASOs to modern siRNA and mRNA-LNP-based therapies. It highlights a growing regulatory trend favoring... -
Japan Accelerates Next-Gen mRNA Vaccine and Therapeutic Development: saRNA and circRNA Boost Immunity and Efficiency
MJA InSight Australia Overview Research into next-generation mRNA vaccines, particularly self-amplifying RNA (saRNA) and circular RNA (circRNA), is rapidly advancing, focusing on enhancing immune durability and efficiency. Beyond infecti... -
6th mRNA Therapeutics Summit Highlights Shift to Oncology, with In Vivo CAR-T, saRNA, and circRNA as Key Innovations
BioSpace USA Overview The 6th mRNA-Based Therapeutics Summit revealed a significant shift in mRNA clinical activity from infectious diseases to oncology, with in vivo CAR-T emerging as a notable application. Self-amplifying RNA (saRNA) a... -
New England Biolabs Unveils Comprehensive RNA Workflow Reagents Supporting mRNA Therapeutics and Diagnostics
New England Biolabs USA Overview New England Biolabs has announced an expanded portfolio of reagents to support various RNA research workflows, including mRNA therapeutics, personalized medicine, and diagnostics. The company highlights t... -
Schrödinger Unveils ‘Bunsen’ AI Co-Scientist to Accelerate End-to-End Biologics Discovery Workflow with BioLuminate and LiveDesign Integration
Schrödinger USA Overview Schrödinger is hosting an event to demonstrate an integrated, end-to-end workflow accelerating biologics discovery and engineering through BioLuminate and LiveDesign. A highlight of this session is the introducti...
